Recurrent infection with Pseudomonas aeruginosa during eculizumab therapy in an allogeneic hematopoietic stem cell transplant recipient

Transplant Infectious Disease

Volumn 18, Issue 2, 2016, Pages 312-314

  Webb, Brandon J ^a   Healy, R ^b   Child, B ^b   Majers, J ^b   Anand, S ^c   Gouw, L ^b  

^a INTERMOUNTAIN HEALTHCARE   (United States)

^b LDS HOSPITAL   (United States)

^c INTERMOUNTAIN MEDICAL CENTER   (United States)

Author keywords

Complement; Eculizumab; Hematopoietic stem cell transplant; Pseudomonas aeruginosa

Indexed keywords

BUSULFAN; CORTICOSTEROID; CYCLOPHOSPHAMIDE; CYCLOSPORIN; ECULIZUMAB; FLUDARABINE; MYCOPHENOLATE MOFETIL; MONOCLONAL ANTIBODY;

ADULT; ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION; CASE REPORT; CORTICOSTEROID THERAPY; DRUG MEGADOSE; GRAFT RECIPIENT; GRAFT VERSUS HOST REACTION; HEMOLYTIC UREMIC SYNDROME; HODGKIN DISEASE; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; LETTER; LOW DRUG DOSE; MALE; PRIORITY JOURNAL; PSEUDOMONAS AERUGINOSA; PSEUDOMONAS INFECTION; PSEUDOMONAS PNEUMONIA; RECURRENT INFECTION; ADVERSE EFFECTS; ATYPICAL HEMOLYTIC UREMIC SYNDROME; BACTERIAL PNEUMONIA; FATALITY; HEMATOPOIETIC STEM CELL TRANSPLANTATION; IMMUNOCOMPROMISED PATIENT; MICROBIOLOGY;

ADULT; ANTIBODIES, MONOCLONAL, HUMANIZED; ATYPICAL HEMOLYTIC UREMIC SYNDROME; FATAL OUTCOME; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HODGKIN DISEASE; HUMANS; IMMUNOCOMPROMISED HOST; MALE; PNEUMONIA, BACTERIAL; PSEUDOMONAS AERUGINOSA; PSEUDOMONAS INFECTIONS;

EID: 84963677224     PISSN: 13982273     EISSN: 13993062     Source Type: Journal    
DOI: 10.1111/tid.12517     Document Type: Letter

References (10)

1. Rother RP, Rollins SA, Mojcik CF, Brodsky RA, Bell L. Discovery and development of the complement inhibitor eculizumab for the treatment of paroxysmal nocturnal hemoglobinuria. Nat Biotechnol 2007; 25 (11): 1256-1264.
2. Rathbone J, Kaltenthaler E, Richards A, Tappenden P, Bessey A, Cantrell A. A systematic review of eculizumab for atypical haemolytic uraemic syndrome (aHUS). BMJ Open 2013; 3 (11): e003573.
3. Struijk GH, Bouts AH, Rijkers GT, Kuin EA, ten Berge IJ, Bemelman FJ. Meningococcal sepsis complicating eculizumab treatment despite prior vaccination. Am J Transplant 2013; 13 (3): 819-820.
4. Hann S, Holsclaw DS. Interactions of Pseudomonas aeruginosa with immunoglobulins and complement in sputum. Infect Immun 1976; 14 (1): 114-1147.
5. Mueller-Ortiz SL, Drouin SM, Wetsel RA. The alternative activation pathway and complement component C3 are critical for a protective immune response against Pseudomonas aeruginosa in a murine model of pneumonia. Infect Immun 2004; 72 (5): 2899-2906.
6. Schiller NL. Characterization of the susceptibility of Pseudomonas aeruginosa to complement-mediated killing: role of antibodies to the rough lipopolysaccharide on serum-sensitive strains. Infect Immun 1988; 56 (3): 632-639.
7. Mishra M, Byrd MS, Sergeant S, et al. Pseudomonas aeruginosa Psl polysaccharide reduces neutrophil phagocytosis and the oxidative response by limiting complement-mediated opsonization. Cell Microbiol 2012; 14 (1): 95-106.
8. Younger JG, Shankar-Sinha S, Mickiewicz M, et al. Murine complement interactions with Pseudomonas aeruginosa and their consequences during pneumonia. Am J Respir Cell Molec Biol 2003; 29 (4): 432-438.
9. Schiller NL, Joiner KA. Interaction of complement with serum-sensitive and serum-resistant strains of Pseudomonas aeruginosa. Infect Immun 1986; 54 (3): 689-694.
10. Krid S, Roumenina LT, Beury D, et al. Renal transplantation under prophylactic eculizumab in atypical hemolytic uremic syndrome with CFH/CFHR1 hybrid protein. Am J Transplant 2012; 12 (7): 1938-1944.